Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Schaepelynck

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
Diabetes & Metabolism|February 16, 2007
Implantable insulin pumps. A position statement about their clinical useE Renard, P Schaepelynck-Bélicar,
Diabetes & Metabolism|October 4, 2003
Reproducibility of plasma insulin kinetics during intraperitoneal insulin treatment by programmable pumpsP Schaepelynck Bélicar, P Vague, V Lassmann-Vague
Diabetes & Metabolism|April 2, 2005
What could be the reasons for giving up the implanted pump treatment?P Schaepelynck-Bélicar, L Dufaitre-Patouraux, V Lassmann-Vague
Diabetes & Metabolism|January 7, 2004
Improved metabolic control in diabetic adolescents using the continuous glucose monitoring system (CGMS)P Schaepelynck-Bélicar, Ph Vague, G Simonin, et al.
Diabetes & Metabolism|January 3, 2012
Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumpsP Schaepelynck, P Darmon, L Molines, et al.
Diabetes & Metabolism|June 30, 2009
Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1 and type 2 diabetes patientsE Cosson, E Hamo-Tchatchouang, L Dufaitre-Patouraux, et al.
Diabetes & Metabolism|January 7, 2004
Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experienceH Gin, E Renard, V Melki, et al.
Diabetes, Obesity & Metabolism|September 11, 2009
A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusionA Liebl, R Hoogma, E Renard, et al.
Journal of Endocrinological Investigation|December 26, 2025
Safety and glycemic outcomes of DBLG1 coupled to the DANA-i pump in adults and adolescents with type 1 diabetes mellitus. The SP8 trialSylvia Franc, Y Reznik, C Amadou, et al.
Diabetes & Metabolism|August 12, 2015
Indication, organization, practical implementation and interpretation guidelines for retrospective CGM recording: A French position statementM Joubert, S Baillot-Rudoni, B Catargi, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Diabetes & Metabolism|February 16, 2007
Implantable insulin pumps. A position statement about their clinical useE Renard, P Schaepelynck-Bélicar,
Diabetes & Metabolism|October 4, 2003
Reproducibility of plasma insulin kinetics during intraperitoneal insulin treatment by programmable pumpsP Schaepelynck Bélicar, P Vague, V Lassmann-Vague
Diabetes & Metabolism|April 2, 2005
What could be the reasons for giving up the implanted pump treatment?P Schaepelynck-Bélicar, L Dufaitre-Patouraux, V Lassmann-Vague
Diabetes & Metabolism|January 7, 2004
Improved metabolic control in diabetic adolescents using the continuous glucose monitoring system (CGMS)P Schaepelynck-Bélicar, Ph Vague, G Simonin, et al.
Diabetes & Metabolism|January 3, 2012
Advances in pump technology: insulin patch pumps, combined pumps and glucose sensors, and implanted pumpsP Schaepelynck, P Darmon, L Molines, et al.
Diabetes & Metabolism|June 30, 2009
Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1 and type 2 diabetes patientsE Cosson, E Hamo-Tchatchouang, L Dufaitre-Patouraux, et al.
Diabetes & Metabolism|January 7, 2004
Combined improvements in implantable pump technology and insulin stability allow safe and effective long term intraperitoneal insulin delivery in type 1 diabetic patients: the EVADIAC experienceH Gin, E Renard, V Melki, et al.
Diabetes, Obesity & Metabolism|September 11, 2009
A reduction in severe hypoglycaemia in type 1 diabetes in a randomized crossover study of continuous intraperitoneal compared with subcutaneous insulin infusionA Liebl, R Hoogma, E Renard, et al.
Journal of Endocrinological Investigation|December 26, 2025
Safety and glycemic outcomes of DBLG1 coupled to the DANA-i pump in adults and adolescents with type 1 diabetes mellitus. The SP8 trialSylvia Franc, Y Reznik, C Amadou, et al.
Diabetes & Metabolism|August 12, 2015
Indication, organization, practical implementation and interpretation guidelines for retrospective CGM recording: A French position statementM Joubert, S Baillot-Rudoni, B Catargi, et al.
Pageof 2